Suppr超能文献

九项普通人群研究中骨保护素浓度与心血管结局风险:基于文献的荟萃分析(涉及26442名参与者)

Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants.

作者信息

Tschiderer Lena, Willeit Johann, Schett Georg, Kiechl Stefan, Willeit Peter

机构信息

Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.

Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany.

出版信息

PLoS One. 2017 Aug 24;12(8):e0183910. doi: 10.1371/journal.pone.0183910. eCollection 2017.

Abstract

BACKGROUND

Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population.

METHODS

Using the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis.

RESULTS

When comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P<0.001; I2 = 76.8%) for cardiovascular disease, 1.72 for coronary heart disease (1.26, 2.37; P = 0.001; I2 = 83.5%), and 1.58 for stroke (1.18, 2.12; P = 0.002; I2 = 65.2%). Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease). Magnitudes of associations did not differ according to the proportion of males, geographical region, or osteoprotegerin assay manufacturer. There was no evidence for publication bias for any of the outcomes assessed (all P>0.05).

CONCLUSIONS

Elevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation.

摘要

背景

近期的实验和流行病学研究表明,骨保护素作为骨代谢的关键调节因子,可能与血管钙化和动脉粥样硬化有关。我们的目的是可靠地量化普通人群中骨保护素浓度与首次发生心血管疾病结局的发生率之间的关联。

方法

利用电子数据库MEDLINE、EMBASE和Web of Science(1975年1月至2017年4月,无语言限制),确定了9项相关研究,共纳入了从普通人群中招募的26442名参与者。在平均8.5年的随访中,记录了2160例心血管疾病、2123例冠心病和1102例中风结局。将各研究的风险比进行随机效应荟萃分析合并。

结果

将骨保护素浓度处于最高三分位数的个体与最低三分位数的个体进行比较时,心血管疾病的合并风险比为1.83(95%置信区间:1.46,2.30;P<0.001;I² = 76.8%),冠心病为1.72(1.26,2.37;P = 0.001;I² = 83.5%),中风为1.58(1.18,2.12;P = 0.002;I² = 65.2%)。在较年轻的年龄组中关联似乎更强(心血管疾病P = 0.018),在未进行统计调整的研究中(心血管疾病P = 0.023,冠心病P = 0.018),以及可能在测量血浆而非血清中骨保护素的研究中(心血管疾病P = 0.005,冠心病P = 0.018)。关联强度在男性比例、地理区域或骨保护素检测试剂盒制造商方面无差异。在所评估的任何结局中均无发表偏倚的证据(所有P>0.05)。

结论

普通人群中骨保护素浓度升高与心血管疾病发病风险增加有关。这一观察结果背后的机制值得进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7a0/5570489/1a9a4f172072/pone.0183910.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验